<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816439</url>
  </required_header>
  <id_info>
    <org_study_id>090040</org_study_id>
    <secondary_id>09-M-0040</secondary_id>
    <nct_id>NCT00816439</nct_id>
  </id_info>
  <brief_title>Imaging Cannabinoid CB1 Receptors in Alcohol Dependence</brief_title>
  <official_title>Imaging Cannabinoid CB1 Receptors in Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The cannabinoid type 1 (CB1) receptor is a protein found in the brain that is involved with&#xD;
      the effects of marijuana; it may also play a role in the effects of alcohol dependence and&#xD;
      withdrawal. Earlier animal studies have shown that although long-term alcohol use decreases&#xD;
      the number of CB1 receptors in the brain, the number returns to normal after alcohol use&#xD;
      stops. This study will use positron emission tomography (PET) and magnetic resonance imaging&#xD;
      (MRI) scans to trace a radioactive chemical called [11C]MePPEP, which can locate and measure&#xD;
      the number of CB1 receptors in the brain. Researchers will study the CB1 receptors in the&#xD;
      brains of people with alcohol dependence, and compare the results to the CB1 receptors in the&#xD;
      brains of people without alcohol dependence. The results of this study will be used to&#xD;
      further research into appropriate treatment procedures for alcohol dependence.&#xD;
&#xD;
      This study will include 30 men with alcohol dependence and 50 men without alcohol dependence.&#xD;
      All of the men must be between 18 and 65 years of age. Participants in both groups must not&#xD;
      have any medical conditions that will prevent them from undergoing PET or MRI scans.&#xD;
&#xD;
      For the PET scan, participants will be injected with a small amount of [11C]MePPEP and will&#xD;
      then be brought to the PET scanner. The scan will take between 3 and 4 hours, but&#xD;
      participants will be allowed to take breaks over the course of the scan. The MRI scan will&#xD;
      not require any injections and will take approximately 1 hour to complete.&#xD;
&#xD;
      Participants without alcohol dependence will make three visits to the National Institutes of&#xD;
      Health Clinical Center. Blood and urine samples will be taken during one visit, and&#xD;
      participants will arrange to have an MRI scan on one visit and a PET scan on the other visit,&#xD;
      in whichever order they prefer.&#xD;
&#xD;
      Participants with alcohol dependence will undergo two PET scans: the first will be performed&#xD;
      between 3 and 7 days after the participant last consumed alcohol, and the second will be&#xD;
      performed approximately 2 to 4 weeks after the first scan (with no alcohol consumption&#xD;
      permitted in the interval). Participants will alcohol dependence will also undergo an MRI&#xD;
      scan and will provide blood and urine samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol dependence (alcoholism) is a chronic medical illness with a relapsing course and a&#xD;
      major public health problem. Alcoholism is clinically characterized by periods of&#xD;
      uncontrolled alcohol consumption and withdrawal, during which counter-adaptive mechanisms&#xD;
      such as stress and dysphoria are recruited. Neurobiological research into the pathophysiology&#xD;
      of the illness suggest that both the primary rewarding effects of ethanol as well as&#xD;
      neuroadaptive changes that occur during chronic alcohol exposure involve persistent changes&#xD;
      in various brain neurotransmission systems, such as the dopamine, glutamate, and gamma-amino&#xD;
      butyric acid (GABA) systems. Recent views of the illness also emphasize the long-lasting&#xD;
      recruitment of the brain stress system. Unfortunately, despite this progress, available&#xD;
      pharmacological agents for the treatment of alcoholism are too few and not sufficiently&#xD;
      efficacious.&#xD;
&#xD;
      The brain endocannabinoid (EC) system is a recently discovered brain neurotransmission&#xD;
      system, which involves endogenous cannabinoid agents (ECs) that act upon specific receptors&#xD;
      (CB1 and CB2). CB1 receptor is abundant in the human brain and acts as an inhibitory&#xD;
      modulator of classical neurotransmitters. ECs and CB1 receptors appear to modulate the brain&#xD;
      reward system, and animal studies have demonstrated an important role of CB1 receptor&#xD;
      stimulation in alcohol- and drug-related behaviors. During chronic alcohol exposure, EC&#xD;
      levels in the brain are elevated and CB1 receptor levels are consequently reduced; this&#xD;
      appears to be reversible following withdrawal. Animal studies suggest that CB1 receptor&#xD;
      blockade in the abstinent phase may reduce alcohol craving and relapse. To what extent ECs&#xD;
      and CB1 receptors are involved in the pathophysiology of alcohol dependence in humans is&#xD;
      currently unknown. The lack of suitable methods to reliably quantify CB1 receptors in the&#xD;
      living human brain has to date hindered the progress in this field.&#xD;
&#xD;
      In this protocol, we outline studies aiming at elucidating the role of CB1 receptors in&#xD;
      alcohol and cannabis dependence by using positron emission tomography (PET) and the recently&#xD;
      developed radiotracer for CB1 receptors, [(18)F]FMPEP-d2. The aim of this project is to&#xD;
      explore CB1 receptor abnormalities at various stages of alcohol and cannabis dependence in&#xD;
      humans. For the studies in alcohol dependence, the primary hypothesis is that CB1 receptors&#xD;
      are downregulated during chronic alcohol exposure and upregulated during extended abstinence.&#xD;
      For the studies in cannabis users, our primary hypothesis is that CB1 receptors are&#xD;
      downregulated during chronic cannabis use and upregulated during extended abstinence. Insight&#xD;
      into the role of CB1 receptor function in human alcoholism and in chronic cannabis use may&#xD;
      help guide future development of pharmacotherapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 29, 2008</start_date>
  <completion_date>August 28, 2014</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">101</enrollment>
  <condition>Alcoholism</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        ALCOHOL DEPENDENT SUBJECTS:&#xD;
&#xD;
          1. All subjects must be male, 18-65 years of age and be able to give written informed&#xD;
             consent.&#xD;
&#xD;
          2. All subjects must be healthy based on history and physical examination.&#xD;
&#xD;
          3. Subjects must fulfill DSM-IV criteria (American Psychiatric Association 1987) for&#xD;
             alcohol dependence. In addition, they must have an alcohol consumption of 35 or more&#xD;
             standard drinks per week, as measured by timeline follow-back during the 28-day period&#xD;
             preceding admission, as well as during the 7-day period immediately preceding it.&#xD;
&#xD;
          4. About half of the patients with alcohol dependence will be carriers of the C allele of&#xD;
             the rs2023239 SNP and half will not.&#xD;
&#xD;
        HEALTHY SUBJECTS:&#xD;
&#xD;
          1. All subjects must be male, 18-65 years of age and be able to give written informed&#xD;
             consent.&#xD;
&#xD;
          2. This comparison group must be healthy based on history and physical examination.&#xD;
&#xD;
          3. About half of the healthy subjects will currently smoke cigarettes and about half will&#xD;
             not.&#xD;
&#xD;
          4. About half of the healthy subjects will be carriers of the C allele of the rs2023239&#xD;
             SNP and half will not.&#xD;
&#xD;
        CANNABIS USERS:&#xD;
&#xD;
          1. All subjects must be male, 18-65 years of age and be able to give written informed&#xD;
             consent.&#xD;
&#xD;
          2. All subjects must be healthy based on history and physical examination.&#xD;
&#xD;
          3. Self-reported cannabis use of at least one year with a typical pattern of use of at&#xD;
             least 5 days per week for the six months prior to unit admission.&#xD;
&#xD;
          4. A positive urine cannabinoid test within 90 days of admission.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        ALCOHOL DEPENDENT PATIENTS:&#xD;
&#xD;
          1. Any serious medical condition as judged by the investigator in consultation with the&#xD;
             attending physician in the NIAAA program.&#xD;
&#xD;
          2. Clinically significant coagulopathies or laboratory abnormalities other than those&#xD;
             related to alcohol dependence.&#xD;
&#xD;
        Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic&#xD;
        disorder; any current disorder that has required psychoactive medication (other than&#xD;
        oxazepam) within the preceding 28-day period (42 days for fluoxetine). 3. Oxazepam is a&#xD;
        relatively short acting benzodiazepine and is used clinically during alcohol withdrawal.&#xD;
        Any present substance abuse other than alcohol.&#xD;
&#xD;
        4. Positive test for HIV.&#xD;
&#xD;
        5. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of&#xD;
        enclosed spaces likely to make the subject unable to undergo an MRI scan.&#xD;
&#xD;
        6. Head trauma resulting in a period of unconsciousness lasting longer than 1 hour.&#xD;
&#xD;
        7. History of fetal alcohol syndrome or other neurodevelopmental disorder.&#xD;
&#xD;
        8. History of seizures, other than in childhood and related to fever.&#xD;
&#xD;
        9. Recent exposure to radiation (i.e., PET from other research) which when combined with&#xD;
        this study would be above the allowable limits.&#xD;
&#xD;
        10. Positive urine drug screen.&#xD;
&#xD;
        11. Inability to lie flat on camera bed for about 2.5 h&#xD;
&#xD;
        HEALTHY SUBJECTS:&#xD;
&#xD;
          1. Any current Axis I diagnosis; and any lifetime diagnosis of drug abuse or dependence.&#xD;
&#xD;
          2. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          3. Recent heavy use of alcohol. That is, subjects must have an alcohol audit score of&#xD;
             less than or equal to 9. In addition, subjects must agree not to consume any alcohol&#xD;
             in the three days prior to the PET scan.&#xD;
&#xD;
          4. Psychotropic medication use (including benzodiazepines and illicit drugs) during the&#xD;
             28 days (42 day for fluoxetine) prior to the PET scan.&#xD;
&#xD;
          5. Serious medical problems.&#xD;
&#xD;
          6. Positive test for HIV.&#xD;
&#xD;
          7. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed&#xD;
             spaces likely to make the subject unable to undergo an MRI scan.&#xD;
&#xD;
          8. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.&#xD;
&#xD;
          9. History of fetal alcohol syndrome or other neurodevelopmental disorder.&#xD;
&#xD;
         10. History of seizures, other than in childhood and related to fever.&#xD;
&#xD;
         11. Recent exposure to radiation (i.e., PET from other research) which when combined with&#xD;
             this study would be above the allowable limits.&#xD;
&#xD;
         12. Positive urine drug screen.&#xD;
&#xD;
         13. Inability to lie flat on camera bed for about 2.5 h&#xD;
&#xD;
        EXCLUSION CRITERIA: CANNABIS USERS:&#xD;
&#xD;
          1. History or presence of any clinically significant illness, as determined by history,&#xD;
             physical examination, and/or laboratory tests.&#xD;
&#xD;
          2. Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic&#xD;
             disorder; any current disorder that has required psychoactive medication within the&#xD;
             preceding 28-day period (42 days for fluoxetine).&#xD;
&#xD;
          3. Current physical dependence on any substance other than cannabis, nicotine, or&#xD;
             caffeine;&#xD;
&#xD;
          4. Positive test for HIV.&#xD;
&#xD;
          5. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of&#xD;
             enclosed spaces likely to make the subject unable to undergo an MRI scan.&#xD;
&#xD;
          6. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.&#xD;
&#xD;
          7. History of fetal alcohol syndrome or other neurodevelopmental disorder.&#xD;
&#xD;
          8. History of seizures, other than in childhood and related to fever.&#xD;
&#xD;
          9. Recent exposure to radiation (i.e., PET from other research) which when combined with&#xD;
             this study would be above the allowable limits.&#xD;
&#xD;
         10. Inability to lie flat on camera bed for about 2.5 h.&#xD;
&#xD;
         11. Regular use of alcohol (greater than or equal to 6 standard drinks per day) four or&#xD;
             more times per week in the month prior to study entry.&#xD;
&#xD;
         12. Currently interested in or participating in drug abuse treatment, or participated in&#xD;
             drug abuse treatment within 60 days preceding study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Innis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Basavarajappa BS, Hungund BL. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. 2005 Jan-Feb;40(1):15-24. Epub 2004 Nov 18. Review.</citation>
    <PMID>15550443</PMID>
  </reference>
  <reference>
    <citation>Brown AK, George DT, Fujita M, Liow JS, Ichise M, Hibbeln J, Ghose S, Sangare J, Hommer D, Innis RB. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res. 2007 Jan;31(1):28-32.</citation>
    <PMID>17207098</PMID>
  </reference>
  <reference>
    <citation>Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Berm√∫dez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR; European TARGALC Consortium. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005 Apr;21(8):2243-51.</citation>
    <PMID>15869521</PMID>
  </reference>
  <verification_date>August 28, 2014</verification_date>
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>December 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Brain Imaging</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

